6 rezultatus
TECHNICAL FIELD
The invention is directed at certain ornithine and lysine derivatives which are selective, mechanism-based inactivators of neuronal isoform of nitric oxide synthase and selective inhibitors of nitric oxide synthase.
BACKGROUND OF THE INVENTION
Nitric oxide synthase (NOS) catalyzes
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin
TECHNICAL FIELD
The invention is directed to novel inhibitors of biological nitric oxide formation.
BACKGROUND OF THE INVENTION
For several decades nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. It has been shown that nitroglycerin